Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

NCT07260435 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: ADT plus only 12 months of ARPI
DRUG: ADT plus continued ARPI

Sponsor

Nick Beije

Collaborators

[object Object]